Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy

Journal of Nuclear Cardiology

Volumn 14, Issue 6, 2007, Pages 852-859

  Nishioka, Silvana A D'Orio ^a   Martinelli Filho, Martino ^a   Brandão, Simone C Soares ^a   Giorgi, Maria Clementina ^a   Vieira, Marcelo L C ^a   Costa, Roberto ^a   Mathias, Wilson ^a   Meneghetti, José Cláudio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cardiac MIBG scintigraphy; Cardiac resynchronization therapy; chronic heart failure; prognosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART SCINTISCANNING; HUMAN; MALE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QRS COMPLEX; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; SYMPATHETIC TONE; TREATMENT INDICATION; TREATMENT RESPONSE;

3-IODOBENZYLGUANIDINE; ADULT; AUTONOMIC NERVOUS SYSTEM DISEASES; CARDIAC OUTPUT, LOW; CARDIAC PACING, ARTIFICIAL; FEMALE; HUMANS; MALE; PROGNOSIS; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 36048952072     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2007.08.004     Document Type: Article

References (33)

1. Cazeau S., Leclercq C., Lavergne T., Walker S., Varma C., Linde C., et al., Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 (2001) 873-880
2. Abraham W.T., Fisher W.G., Smith A.L., Delurgio D.B., Leon A.R., Loh E., et al., MIRACLE Study Group. Multicenter In Sync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
3. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005); the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
4. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
5. Khand A., Gemmel J., Clark A.L., and Cleland J.G.F. Is the prognosis of heart failure improving?. J Am Coll Cardiol 36 (2000) 2284-2286
6. Bonow R.O., Bennett S., Casey D.E., Ganiats T.G., Hlatky M.A., Konstam M.A., et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol 46 (2005) 1144-1178
7. Yu C.M., Zhang Q., Fung J.W., Chan H.C., Chan Y.S., Yip G.W., et al. A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging. J Am Coll Cardiol 45 (2005) 677-684
8. Rosanio S., Schwarz E.R., Ahmad M., Jammula P., Vitarelli A., Uretsky B.F., et al. Benefits, unresolved questions, and technical issues of cardiac resynchronization therapy for heart failure. Am J Cardiol 96 (2005) 710-717
9. Strickberger S.A., Conti J., Daoud E.G., Havranek E., Mehra M.R., Piña I.L., and Young J. Patient selection for cardiac resynchronization therapy: from the Council on Clinical Cardiology Subcommittee on Electrocardiography and Arrhythmias and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation 111 (2005) 2146-2150
10. Bax J.J., Abraham T., Barold S.S., Breithardt O.A., Fung J.W., Garrigue S., et al. Cardiac resynchronization therapy. Part 1-issues before device implantation. J Am Coll Cardiol 46 (2005) 2153-2167
11. Marcassa C., Campini R., Verna S., Ceriani L., and Giannuzzi P. Assessment of cardiac asynchrony by radionuclide phase analysis: correlation with ventricular function in patients with narrow or prolonged QRS interval. Eur J Heart Fail 9 (2007) 484-490
12. 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 86 (2001) 656-660
13. Flotats A., and Carrió I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 11 (2004) 587-602
14. Anastasiou-Nana M.I., Terrovitis J.V., Athanasoulis T., Karaloizos L., Geramoutsos A., Pappa L., et al. Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 96 (2005) 427-431
15. Matsui T., Tsutamoto T., Maeda K., Kusukawa J., and Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J 66 (2002) 537-543
16. Agostini D., Belin A., Amar M.H., Darlas Y., Hamon M., Grollier G., et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med 41 (2000) 845-851
17. Suwa M., Otake Y., Moriguchi A., et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 133 (1997) 352-358
18. Kasama S., Toyama T., Kumakura H., Takayama Y., Ichikawa S., Suzuki T., et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 45 (2005) 661-667
19. Toyama T., Hoshizaki H., Seki R., Isobe N., Adachi H., Naito S., et al. Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy. J Nucl Med 44 (2003) 1604-1611
20. Choi J.Y., Lee K.H., Hong K.P., Kim B.T., Seo J.D., Lee W.R., and Lee S.H. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol 8 (2001) 4-9
21. Gerson M.C., Craft L.L., McGuire N., Suresh D.P., Abraham W.T., and Wagoner L.E. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 9 (2002) 608-615
22. Erol-Yilmaz A., Verberne H.J., Schrama T.A., Hrudova J., De Winter R.J., Van Eck-Smit B.L., et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 28 (2005) 304-310
23. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantification of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
24. 131I)iodobenzylguanidine. J Nucl Med 21 (1980) 349-353
25. Dae M.W., O'Connell J.W., Botvinick E.H., Ahearn T., Yee E., Huberty J.P., et al. Scintigraphic assessment of regional cardiac innervation. Circulation 79 (1989) 634-644
26. Merlet P., Benvenuti C., Moyse D., Pouillart F., Dubois-Randé J.L., Duval A.M., et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 40 (1999) 917-923
27. Unverferth D.V., Magorien R.D., Moeschberger M.L., Baker P.B., Fetters J.K., and Leier C.V. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 54 (1984) 147-152
28. Florea V.G., Henein M.Y., Cicoira M., Anker S.D., Doehner W., Ponikowski P., et al. Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure. Am J Cardiol 86 (2000) 158-161
29. Merlet P., Valette H., Dubois-Randé J.L., Moyse D., Duboc D., Dove P., et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33 (1992) 471-477
30. Parthenakis F.I., Patrianakos A., Prassopoulos V., Papadimitriou E., Nikitovic D., Karkavitsas N.S., et al. Relation of cardiac sympathetic innervation to proinflammatory cytokine levels in patients with heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 91 (2003) 1190-1194
31. Gerson M.C., McGuire N., and Wagoner L.E. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 9 (2003) 384-391
32. Greenberg B., and Mehra M.R. All patients with heart failure and intraventricular conduction defect or dyssynchrony should not receive cardiac resynchronization therapy. Circulation 114 (2006) 2685-2691
33. Yamashina S., and Yamazaki J.-I. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging 31 (2004) 1353-1355